SGPSpyGlass Pharma, Inc.
$24.70
$24.70
$17.5652 weeks$29.68
Price
End-of-day closes, not the intraday tick.
The five questions
1 of 5 availableOnly one of the five can be answered for SGP today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?not enough filed
P/En/a
Market value$825.8M
1 yearn/a
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 5, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 1, 2026On October 1, 2026, the Company entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Santen Holdings US, Inc., a California corporation (“Seller”), and Santen Pharmaceutical Co., Ltd., a Japanese Company (“Parent”)Regulation FD disclosure · Form 8-K
- Aug 6, 2026SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates.Earnings release · press release
- May 14, 2026SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry